Here is a great opportunity to go long on NVCR.
At Three Percent Trades we have a price target of $90.00 / share, which is a potential upside of 14.1% from the current level.
We use a combination of fundamentals & technical analysis to trade high probability set-ups, and believe this is a great opportunity to take advantage.
1. Not up three days in a row
2. Linear move up prior to consolidation
3. Young Trend
4. No breakouts or breakdowns during consolidation phase
5. Clean and low volatility consolidation
***see roboticinvesting.com for more details on Momentum Surge
1. Not up three days in a row
2. Linear move up prior to consolidation
3. Young Trend
4. No breakouts or breakdowns during consolidation phase
5. Clean and low volatility consolidation
***see roboticinvesting.com for more details on Momentum Surge
NVCR looks like it will have a promising next couple months if it stays consistent with the channel as it just bounced of the support line today. Bottom support has now been tested 3x. Should be promising.
Great chart pattern with clearance of some key fib levels, positive momentum, and large volume breakout, off of a 6-7 month trading range.
Bought some outright shares on Friday, as the options are thinly traded.
Happy Trading
Lindosskier
Catalyst is JPM healthcare conference presentation 1/10/17. Good volume and made all time highs. Didn't move intraday but it still seems like a confirmed brakeout. 6 month consolidation could get explosive.
Industry:Medical Equipment, Supplies & Distribution
Employees:598
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
NVCR
